Rxo (RXO) Revenue (2021 - 2026)

Rxo (RXO) has reported Revenue for 6 consecutive years, with $1.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 25.02% year-over-year to $1.8 billion; the trailing twelve-month figure through Jun 2026 stood at $6.1 billion (up 9.53% YoY), and the FY2025 full-year result was $5.7 billion, up 26.2% from the prior year.
• Revenue improved to $1.8 billion in Q2 2026 per RXO's latest filing, from $1.4 billion in the prior quarter.
• Across five years, Revenue topped out at $1.8 billion in Q2 2026 and bottomed at $913.0 million in Q1 2024.
• Historically, Revenue has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2022.
• The sharpest annual moves came in 2023 and 2024: Revenue retreated 23.02% in 2023, then surged 70.45% in 2024.
• Over 5 years, Revenue stood at $1.1 billion in 2022, then slipped by 12.68% to $978.0 million in 2023, then soared by 70.45% to $1.7 billion in 2024, then retreated by 11.88% to $1.5 billion in 2025, then increased by 20.76% to $1.8 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $1.8 billion, $1.4 billion, and $1.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.